Implant Intro Flashcards

1
Q

What are questions to ask when evaluating for implant placement

A
Bone Quantity good?
Bone Qualit good?
Soft tissue Quantity
Soft tissue Quality
Can it be placed now?
Is prep work needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Albrektsson Criteria for sucess

A
  • No mobility
  • No peri implant radiolucency
  • vertical bone loss less than .2mm after first year
  • absence of signs/symptoms of pain, paresthesia, infection, etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Other criteria for implant sucess

A
  • Oseointegration
  • functional restoration
  • acceptable esthetics
  • long term tissue health
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prereqs to implant therapy

A

Med hx
Dent Hx
Oral health status
adequate soft tissues and bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diabetes and Implant success

A

-mixed results but most studies don’t look at control of diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Oates 2014

A

No evidence of altered implant survival with elevated HbA1c, BUT looked only at edentulous patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Osteoporosis and Implants

A

No difference between studied groups

-unless smoking involved then 2.6% increase in failure rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

2 types of drugs for osteoporosis

A
  • Antiresorptive drugs

- Antiangiogenisis agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Antiresorptive drugs

A

alter bone metabolism mainly by inhibiting osteoclast function; altered bone metabolism in patients with bone cancers
– Bisphosphonates
– RANK ligand inhibitor (denosumab) – (monoclonal antibody
to RANK ligand (RANK‐L)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Antiangiogenisis agents

A

Antiangiogenesis agents – interfere with new blood
vessel formation; used in patients with certain types of
tumors/cancers (sunitinib, sorafenib, bevacizumab,
sirolimus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bisphosphonates

A

– decrease osteoclastic activity
– Oral agents:
•Alendronate (Fosamax), Risedronate (Actonel), Ibandronate
(Boniva)
–IV agents:
•Pamidronate (Aredia); Zolendronate (Zometa)
– given IV once every few weeks or months (mainly for bone
malignancy or Paget’s disease; used in some severe osteoporosis
cases)
• Reclast
– Yearly IV infusion of zolendronate for osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

“Osteonecrosis of the jaw”

A

originally
identified in patients taking bisphosphonates
– seen after invasive procedure like flap surgery,
implant placement or tooth extraction; spontaneous
cases have frequently been reported (make up large
percentage of cases)
– signs of ONJ: jaw pain, exposed bone, tooth mobility,
numbness, bone sequestration (similar to
osteoradionecrosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bisphosphonate mechanism

A

• Bisphosphonates bind to bone mineral with minimal
metabolism of the drug
• Drugs are internalized by osteoclasts, resulting in:
– inhibition of osteoclast recruitment
– inhibition of osteoclastic activity
– decreased osteoclast life span
• Drugs also inhibit endothelial cell function in bone:
– may impair blood supply to bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which has greater risk for causing MRONJ, oral or IV infusible

A

Infusible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Does risk of MRONJ decrease after discontinuation of drug

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Stats for MRONJ risk of different drugs in cancer patients

A

•Risk of ONJ in cancer patients taking placebo in clinical
trials = 0 ‐ 0.019% (0‐1.9 cases per 10,000 patients)
•Risk of ONJ in cancer patients taking zolendronate =
0.7‐ 6.7% (70‐670 cases per 10,000 patients)
– 50‐350 times higher risk for IV zolendronate than placebo
•Risk of ONJ in cancer patients taking denosumab = 0.7‐
1.9% (70‐190 cases per 10,000 patients)
– risk close to zolendronate
•Risk of ONJ in cancer patients taking bevacizumab
(antiangiogenic agent) = 0.2% (20 cases per 10,000)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

MRONJ stats of different drugs in patients with osteoporosis

A

•Risk of ONJ in large, long‐term studies of oral
bisphosphonates for osteoporosis was 0.1% (10 cases
per 10,000), which increased to 0.21 (21 cases per
10,000) among patients with greater than 4 years of
oral BP exposure
•Risk for ONJ among patients treated for osteoporosis
with either zolendronate annually (Reclast) or
denosumab semi‐annually (Prolia) (0.017 – 0.04%)
approximates the risk for ONJ of patients enrolled in
placebo groups (0%‐0.02%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Take homes of MRONJ

A

•Risk of ONJ for drug regimens used to treat
osteoporosis is more than 100 times lower than risk
for drug regimens used to treat cancer
•Risk for ONJ does increase with time of use (for both
cancer regimens and osteoporosis regimens)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dental guidelines for MRONJ at risk pos (IV)

A

IV agents: Procedures that involve direct osseous injury
should be avoided. Recommend no surgery (including ext)
in patients taking IV agents (do endo, coronectomy, etc,
rather than ext tooth); recommend no dental implants in
these patients.
• If patient is about to start IV agents, try to remove teeth with
poor prognosis ahead of time and make sure patient’s oral health
is good before drug initiation
2014

INFORMED CONSENT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MRONJ risk pt oral med Dental guidelines

A

-patients taking oral agents < 4 years and have no other”
“clinical risk factors (e.g., diabetes, corticosteroids, smoking, alcohol, poor OH, chemotherapy, etc.): no alteration in planned surgery. If implants are placed,”
“nformed consent concerning possible future implant failure.”

• Patients taking oral agents > 4 years with or without any
concomitant medical therapy (steroids/antiangiogenic
agents): contact prescribing physician to discuss
discontinuation of drug for 2 months prior to oral surgical
therapy and until after bony healing is complete (which
could be several months after tx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

MRONJ drug holiday

A

dictated by physician not dentist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are some medications types that might alter surgical plan

A

– anticoagulants (Coumadin/warfarin)
–diabetes medications (e.g., insulin)
–CNS depressants, especially if conscious sedation is
to be used (antidepressants, antianxiety agents,
some antihistamines, others)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Radiation therapy impact on Implants

A

– Increases risk of implant failure (and complications such as
osteoradionecrosis)
– Failure rate dependent on total radiation dose
• 2.6% failure rate with <55Gy total radiation
• 10.1% failure rate with >55Gy total radiation
– Hyperbaric oxygen may decrease failure rate, but little direct
evidence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Smoking and Implant SURVIVAL

A

• Systematic review analyzed 14 articles with
implant survival data for smokers (12 to 144
months)
• Overall survival rate:
SMOKERS 89.7%
NONSMOKERS 93.3%
Pooled estimate of difference in overall survival rate was 2.7%
better for nonsmokers (p=0.0009). Statistically significant, but not
clinically impressive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Smoking and Implant SUCCESS
• Analyzed 7 articles with implant success data for smokers (12 to 48 months) – Varying success criteria in articles • Overall success rate: SMOKERS 77.0% NONSMOKERS 91.0% Pooled estimate of difference in overall success rate was 11.3% better for nonsmokers (p=0.005). Statistically significant, and impressive clinical difference.
26
Smoking and Implant big pictures
– Smoking decreases implant survival, but mainly at maxillary sites – Smoking decreases implant success in both maxillary and mandibular sites – Impact of smoking is lower with use of microroughened surfaces than for machined surfaces
27
Does oral health need to be controlled before implants
Yes
28
Periodontitis and survival
– Implant survival lower when subjects had more than 30% of teeth with bone loss >4mm (i.e., history of periodontitis) even if disease was currently under control!
29
Periodontitis and Perioimplantits
O.R. for peri‐implantitis was 4.7 in subjects with >4mm bone loss at >30% of teeth compared to <30% of teeth at time of implant placement • % of subjects who developed peri‐implantitis requiring surgery, and/or systemic or local antibiotics: – Periodontally healthy = 10.7% – Hx of treated moderate periodontitis = 27.0% – Hx of treated severe periodontitis = 47.2%
30
Periodontits and roughened implants
Implant survival rates are slightly lower in patients with past hx of periodontitis, but survival rates are generally >90% with microroughened surfaces
31
Implant PD and periodontitis
– Periodontally healthy = 4.2mm – Hx of treated moderate periodontitis = 5.1mm – Hx of treated severe periodontitis = 5.5mm • % of implants having 6mm PD at 1+ sites during maint: – Periodontally healthy = 6.6% – Hx of treated moderate periodontitis = 29.5% – Hx of treated severe periodontitis = 45.6%
32
Why do you want adequate soft tissue
``` – to cover implant site – to ensure esthetic result – to allow long‐term maintenance of health ```
33
When is it best to treat soft/hard tissue defects
Prior or at implant placement
34
Why do you want adequate hard tissues
``` – to allow for implant placement – to ensure implant stability – to allow long‐term maintenance of health ```
35
What drives implant placement location
Where it needs to be restoratively not where tissues are adequate. If tissues can't be augmented then implant shouldn't be used
36
How is bone located
``` – palpation – bone sounding – radiographs • Incisions should always be placed over bone • Implant must be placed in bone or bone must be augmented Anatomical Considerations • Where is the bone?? – palpation •Least accurate technique •Can determine gross bony contours •Often overestimates/underestimates amount of bone truly present ```
37
Palpating Bone
``` •Least accurate technique •Can determine gross bony contours •Often overestimates/underestimates amount of bone truly present The time to find out how much bone you have is not the day of surgery ```
38
Bone sounding
``` • patient is anesthetized and probe is placed through soft tissue to bone • bone can be “mapped” and transferred to cast • Better to use template that covers entire F&L ```
39
Radiographic imaging of bone
•Very useful •Can still under/overestimate actual bone •Can choose between many types of radiographs (2‐D and 3‐D) – variations in magnification and image distortion can be critical •3‐D imaging is a huge plus for many patients; not as important for others
40
Radiogrpahic magnification | Stats
``` • Periapical 7% • Panographic 22‐28% • Cross‐sectional view  Linear tomography 10%  Computed tomography 0% ```
41
Areas of anatomic concern for bone levels
```  Nasal floor  Maxillary sinus  Incisive canal  Mental foramen  Mandibular canal ```
42
Surgical Goal of diagnostic phase
Know where bone is before first incision is made
43
Bone resorption and implant placement
``` Severe resorption can affect ability to place implants and patient’s ability to maintain implants – Implant may violate mandibular canal, maxillary sinus, bony concavity – Implant may not be positioned at same angles as the natural tooth • As ridge resorbs, implant placement may violate confines of mandible or maxilla ```
44
What is minimum implant length
Historically 10 mm -Meta‐analyses show that with rough surface implants, survival rates are same for implants <10mm as for implants >10mm
45
Where do stresses concentrate in implants
Coronal Aspects
46
Where is the bested worst density of bone for implant placement
Poorest-max posterior | Best - Man Ant
47
Minimum BL crest width and minimum amount of bone B and L of implant
>7-8mm total with 2 mm buccal and 1.5 mm L
48
How much bone should be between PDL and implant
2mm
49
How much bone between implants
3mm
50
How far apically from gingival margin should the implant be placed
3.4 mm to maintain gingival height | 2-3mm from CEJs of adjacent teeth
51
Platform switch and interplant distance
recent studies show that implants having narrower abutment connection (“platform switch) can be placed closer together than 3mm and not lose inter‐implant bone (some as close as 1.5‐2.0mm) – Keep in mind heat generation and bone trauma during osteotomy preparation on implants placed close together – Keep in mind emergence profile of final restorations for implants placed close together
52
EMERGENCE PROFILE
• The manner in which the restoration emerges through the soft tissue from its base at the implant interface
53
Bone quality and Implant sucess
– Earlier studies suggested that implant survival & success rates decreased in posterior areas of lesser bone quality •This was primarily true with machined Ti surfaces -roughened surfaces may not be as restricted
54
Things to avoid in maxilla
– Nasal cavity – Maxillary sinus – Nasopalatine canal/foramen; greater/lesser palatine foramina
55
Things to avoid in mandible:
– Mandibular canal; mental foramen – Lingual concavities/fossae (e.g., submandibular salivary gland fossa, inferior to mylohyoid ridge) • Perforation of lingual periosteum may have major negative effects (bleeding, nerve trauma)
56
Maxillary sinus
– Lined by Schneiderian membrane – Pneumatization after early tooth loss
57
Max Sinus Septae
``` • Can limit elevation of lateral window during sinus elevation • Increase risk of membrane tear • 13/41 (32%) maxillae with >1 septum • 2/41 (5%) with 2 septa • 73% in premolar region • 20% in first molar region ```
58
Incisive canal
``` • Nasopalatine nerve • Sphenopalatine artery – Remove contents – Bone graft – Only 4% would be in the way of an implant ```
59
Anterior loop of IA nerve
``` • 88% of 22 skulls • 76% bilateral • Length ranged from 1-11mm with mean 4.13 ± 2.04mm ```
60
Anterior Vasculature of Man
``` • Sublingual artery • Submental artery • Incisive artery • Median lingual foramen found 85- 99% • Inferior midline foramen found 76% ```
61
Lingual Artery
``` – Tongue, floor of mouth, lingual mucosa & gingiva – Can be damaged by lingual perforation of blades (uncommon because it is usually deep in floor of mouth & tongue) ```
62
Facial Artery
``` – Palpable at anterior border of masseter m. – Can be damaged by deep facial releasing incisions and by lingual drill perforations in posterior mandible ```
63
Max artery
``` – Gives off the inferior alveolar a. (can be damaged by invasion of mandibular canal) – Gives off palatine arteries (can be damaged by improper palatal incisions) – Gives off posterior superior a. (can be damaged by posterior superior releasing incisions) and sinus window preparation ```
64
palatine arteries
``` – can be damaged by improper palatal incisions (usually releasing incisions made too far posteriorly or carried too far superiorly) – can be damaged by incisions for deep split thickness flaps or connective tissue grafts ```
65
Vasculature to gingiva | and alveolar mucosa
``` – Terminal branches of major vessels – Critical for flap integrity & nourishment – Come from apical region to marginal and papillary gingiva – Can easily be damaged by incisions near base of flaps ```
66
Sensory innervation to most structures of concern
branches of trigeminal nerve (V) – ophthalmic division (V1) – maxillary division (V2) – mandibular division (V3)
67
Surgical Principles
* Provide profound anesthesia * Aseptic technique * Antibiotics * Atraumatic tissue management
68
concentrations of epinephrine > 1:100,000
• Increased concentration (e.g., 1:50,000) causes greater local vasoconstriction but does not increase duration of action • May increase risk of flap necrosis
69
Man implants and anesthesia
For mandibular implants, consider not using inferior alveolar nerve block anesthesia (infiltration only on facial, with block only of lingual nerve) – decreases risk of accidental invasion of mandibular canal – patient will “let you know” if you are getting close to mandibular canal – use of conscious sedation can be an aid in these cases – Digital radiography is BIG plus
70
Aeseptic Surgical Technique
• Pretreatment antimicrobial rinse (e.g., Listerine, CHX) • Sterile instrumentation • Sterile gloves • Do not contaminate implant surface • Use sterile irrigating solutions – Required by current CDC guidelines for any surgical procedure in which bone is exposed (meaning, implant surgery) – Irrigate, irrigate, irrigate (during surgery, implant placement; thorough irrigation under flaps before closure)
71
Antibiotics
• For dental implant surgery, default answer has been “YES” – Based on original Branemark protocol – Very little data to show benefit of antibiotics for implant success/failure
72
New studies and number of patients needed to treat to prevent 1 from having a failure
to prevent one patient from having an implant failure, 33 patients would have to receive pre‐op antibiotics – **2013 update: NNT = 25***
73
Atraumatic Tissue Management
• Sharp, smooth incisions (“an incision heals better than a tear”) • Careful flap reflection and retraction • Avoid flap tension – Watch your assistant!! – Excessive tension on a flap can cause a tear – Excessive pressure during retraction can cause vascular embarrassment to flap or pressure damage to nerves
74
Surgical Technique
* Flap design * Incisions and flap reflection * Implant placement * Hemostasis/suturing
75
Flap Designs
– Envelope flap – Triangular flap – Pedicle flap
76
Envelope Flap
``` – Requires no releasing incisions – The longer the flap, the less tension is placed on the flap during retraction ```
77
Triangular flap
``` – Requires single vertical releasing incision – Vertical releasing incision creates greater access to underlying bone, tooth, implant; less tension on flap than with envelope flap – Can be used to avoid placing releasing incision in esthetic area or area of critical anatomy ```
78
Pedicle Flap
``` – Generally requires two vertical releasing incisions – Biggest benefit is ability to displace flap margin upon closure (apically positioned, coronally positioned, laterally positioned, etc.) – Excellent access to underlying bone, tooth, implant -Flap height to base should not exceed 2:1 – Releasing incisions may be nearly parallel, slight divergent, or widely divergent ```
79
Releasing incisions
– Placement of releasing incisions is critical • Incisions should be over bone •Place releasing incisions at line angles of teeth or implants •Generally do not split papilla with releasing incision •Do not place releasing incisions over root or implant prominences
80
Full thickness (mucoperiosteal) flap
Includes periosteum
81
Partial "Split" thickness flap
Periosteum remains attached to bone
82
Combination flap
``` part full part partial – Usually full thickness in coronal aspect, split thickness apical to mucogingival junction (periosteal releasing incision allows dramatic improvement in flap mobility) – common for procedures requiring coronal flap positioning ```
83
Incision type around teeth or implant
– Sulcular incision | – Inverse bevel (“reverse bevel” or “step‐back”) incision
84
Incision type in edentulous area
– Crestal incision – Vestibular incision – Palatally/Facially displaced incision
85
Sulcular incision
``` – preserves all keratinized tissue – easy to perform – used if clinician is satisfied with the form of the existing marginal & papillary gingiva ```
86
Inverse Bevel
``` – apically positions flap margin – degree of “step back” can vary depending on goal – can be used to change form of existing marginal & papillary tissue (e.g., can make more accentuated scallop) ```
87
Displaced Incision
``` – Incision displaced to facial or lingual/palatal, but not way out in vestibule – Supposedly prevented exposure of implant during healing (except it didn’t) • Palatally displaced incisions increased risk of flap necrosis ```
88
Incision types and success rates
Similar with ALL incisions
89
most common implant incision
Crestal incision with slight off‐set
90
Around teeth or implants…what do I do with the papillary tissues?
may include or not
91
Papillae “preserved” | not included in flap
``` – Papillae remain in place – Good if clinician is happy with current interproximal tissue – May limit surgical access in narrow edentulous areas ```
92
Papillae included in flap
``` – Better access in limited space – Risks “loss” of papillae – Often better approach if bone is to be modified under flap (e.g. GBR procedures) ```
93
General Principles of implant placement
– copious irrigation while drilling (do not overheat bone) – drilling osteotomy done at higher speeds (~800‐1500 rpm, depending on system) • Some systems use slower speeds for larger diameter drills – implant placement done at low speeds (~15‐50 rpm)
94
Temperature of bone necrosis
47C | USAF birth year
95
Memostasis
• Must have good hemostasis before patient release • Pressure, pressure, pressure • Hemostatic agents rarely indicated (but may be helpful with larger bleed) • Do not use anesthetic agents with high epinephrine concentrations (e.g., 1:50,000) as “hemostatic agents” – once the effect wears off, bleeding will resume
96
Perforation of mandibular | lingual cortical plate
``` can lead to major bleeding – Hematoma in floor of mouth – Airway embarrassment or occlusion – Death ```
97
Atraumatic Suture Technique
• Use smallest needle and suture you can for a given area (depending on expected flap tension, etc.) • Put sutures in keratinized tissue if you can (vs. alveolar mucosa) – Better resistance to flap tension – Less discomfort for patient; easier to remove • Take big bites of tissue; keep needle punctures away from flap margins • Minimum number of sutures to achieve closure • Relieve tension from flap margins
98
Obliterate Dead Space
• Eliminate dead space between flap and bone – PRESSURE!! – prevent hematoma formation (hematoma = great culture medium for microorganisms)